EcoDrugPlus

Prostaglandin D2 Receptor 2

Ensembl ID : ENSOTSG00005031848
Gene Symbol: PTGDR2
3 Cross references
141 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSOTSG00005008356
Gene Symbol: PTGDR2
1 Cross references
130 Possible Orthologues:

Prostaglandin E Receptor 1a (Subtype Ep1)

Ensembl ID : ENSOTSG00005037726
Gene Symbol: PTGER1A
1 Cross references
162 Possible Orthologues:

Prostaglandin E Receptor 1b (Subtype Ep1)

Ensembl ID : ENSOTSG00005012229
Gene Symbol: PTGER1B
1 Cross references
158 Possible Orthologues:

Prostaglandin E Receptor 2a (Subtype Ep2)

Ensembl ID : ENSOTSG00005011000
Gene Symbol: PTGER2A
1 Cross references
198 Possible Orthologues:

Prostaglandin E Receptor 2b (Subtype Ep2)

Ensembl ID : ENSOTSG00005005905
Gene Symbol: PTGER2B
1 Cross references
163 Possible Orthologues:

Prostaglandin E Receptor 3

Ensembl ID : ENSOTSG00005002576
Gene Symbol: PTGER3
3 Cross references
195 Possible Orthologues:

Prostaglandin E Receptor 4 (Subtype Ep4) B

Ensembl ID : ENSOTSG00005021968
Gene Symbol: PTGER4B
1 Cross references
195 Possible Orthologues:

Prostaglandin E Receptor 4 (Subtype Ep4) B

Ensembl ID : ENSOTSG00005040707
Gene Symbol: PTGER4B
1 Cross references
195 Possible Orthologues:

Prostaglandin E2 Receptor Ep1 Subtype-Like

Ensembl ID : ENSOTSG00005010510
Gene Symbol: LOC112258820
3 Cross references
159 Possible Orthologues:

Prostaglandin E2 Receptor Ep2 Subtype-Like

Ensembl ID : ENSOTSG00005009719
Gene Symbol: LOC112217917
3 Cross references
163 Possible Orthologues:

Prostaglandin E2 Receptor Ep2 Subtype-Like

Ensembl ID : ENSOTSG00005029045
Gene Symbol: LOC112245276
3 Cross references
163 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).